Huberman is the most quoted voice in peptides and the most selectively quoted. A faithful summary of his two Huberman Lab episodes: the mechanisms he finds credible, the compounds he tells listeners to avoid, and the sourcing advice that almost never survives the clip.
Written by the Peptide Labs Research Team
Search almost any peptide and you will find a clip of Andrew Huberman, PhD (Stanford neurobiology and ophthalmology), saying something encouraging. What the clip leaves out is the ninety seconds either side, which is usually where the caution lives. He has covered peptides at length twice:
| Episode | Date | Format |
|---|---|---|
| Benefits & Risks of Peptide Therapeutics for Physical & Mental Health | 1 April 2024 | Solo |
| Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity | 7 October 2024 | Guest, Craig Koniver, MD |
The first episode is titled "Benefits & Risks", and the risks half runs about as long as the benefits half. This is a summary of his stated positions, with links to check each against the source. He has no connection to this site or any product on it.
Pleiotropy: one molecule does many things at once. A compound that stimulates tissue growth where you want it stimulates growth generally, because its receptors are not confined to the injury. So "it healed my shoulder" and "it may accelerate something you do not know you have" are the same claim seen from two angles.
He is most often clipped on an anecdote about a past disc injury. The mechanism he describes is upregulation of VEGF, driving angiogenesis (new blood vessel growth) at the injury site. The caution is attached to that same mechanism: angiogenesis is not selective, a tumour needs a blood supply, and a class of cancer drugs, bevacizumab among them, works by inhibiting VEGF. He advises anyone with a cancer concern to avoid it, and says the evidence is overwhelmingly animal work plus self-reports, which are not controlled trials.
He describes thymosin beta-4 as a naturally occurring tissue-repair peptide with substantial animal literature and minimal human clinical evidence. It is not a growth-hormone-type compound.
This is the longest section, and it separates compounds that usually get lumped together: GHRH analogues (which prompt the pituitary closer to its natural pulsatile rhythm) and GHRPs / ghrelin mimetics (more potent, and messier).
| Compound | Family | Huberman's stance |
|---|---|---|
| Sermorelin | GHRH | Most favourable of the group, though he reported it reduced his REM sleep |
| Tesamorelin | GHRH | The one analogue with an approved indication (visceral fat in HIV-associated lipodystrophy) |
| CJC-1295 | GHRH + DAC | Advises avoiding, citing a trial death and fluid retention |
| Ipamorelin | GHRP | Relatively selective, but drives hunger and may cost REM sleep |
| Hexarelin | GHRP | Advises strongly against because of prolactin elevation and receptor desensitisation |
| GHRP-2 / GHRP-6 | GHRP | Flags raised cortisol and prolactin as class problems |
| MK-677 | Oral ghrelin mimetic | Same cortisol, prolactin and REM concerns |
Two warnings run underneath. Receptor desensitisation can blunt the response over time. And several of these raise slow-wave sleep while reducing REM, which he treats as a trade rather than an upgrade, since REM does real work for emotional regulation and memory.
On age, he says that under 30 you already produce plenty of growth hormone and there is no physiological rationale for augmenting it without a diagnosed need. The risk-benefit picture shifts with age, but he does not treat that as a green light.
Huberman cites a death in a CJC-1295 trial linked to cardiovascular dysfunction. The published human trial most often cited, Teichman et al., JCEM (2006), reported mostly mild, local adverse events and no serious drug-related events in that dataset. Separately, the developer's programme was discontinued after a participant death publicly characterised as unrelated to the study drug. Both can be true. The durable point is that no long-term human safety data for CJC-1295 exists.
Both episodes land in the same uncomfortable place. Huberman recommends working with a board-certified physician and obtaining material through a compounding pharmacy or pharmaceutical supplier, explicitly not grey-market channels. His concern is lipopolysaccharide (LPS) endotoxin contamination, on top of mislabelling and wrong concentrations. Koniver goes further and advises against buying peptides sold online under research-use-only or not-for-human-consumption labels, citing contamination risk including anaphylaxis.
We supply research-grade peptides, and that advice belongs here unedited. Research-grade purity is a chemical specification. It is not sterility, endotoxin qualification or a pharmaceutical release standard.
Not directly. His advice is aimed at a US audience. In June 2024 Australia became the first country to add BPC-157 to Schedule 4 of the Poisons Standard, making it prescription-only, and other peptides discussed sit in Schedule 4 too. Importing one without a prescription or a TGA pathway is a regulatory breach, and customs seizure is the routine outcome. See research peptide legality in Australia. The pathway he points to runs through a doctor here as well.
1. "Huberman uses BPC-157." He described a specific past experience in an episode that devotes time to the compound's theoretical cancer risk. A disclosure is not a protocol.
2. "Huberman recommends growth hormone peptides." He tells listeners to avoid at least two by name and argues against use under 30.
3. Dosing numbers presented as his prescription. They were descriptions of clinical practice, delivered alongside instructions to work with a physician.
4. Silence on sourcing. It is the most actionable content in both episodes and the least reproduced, because it points away from the channel most people buy through.
Does Andrew Huberman endorse or sell peptides?
No. He has no affiliation with this site or any product on it.
Does he say BPC-157 is safe?
No. He describes a plausible healing mechanism alongside a theoretical cancer risk from that same mechanism, thin human evidence and contamination concerns.
Which peptides does he warn against?
CJC-1295 (trial death, fluid retention) and hexarelin (prolactin elevation, desensitisation), plus cortisol and prolactin concerns across the GHRP family.
Does the podcast give dosing protocols?
Ranges are discussed under physician supervision. This article deliberately omits them.
Disclaimer: This article summarises publicly available podcast content for educational purposes and is not medical advice. Andrew Huberman, PhD, and Craig Koniver, MD, are not affiliated with Peptide Labs, have not endorsed this site or any product on it, and are cited here solely as sources whose published statements are being reported. Quotations and positions are paraphrased summaries; consult the linked episodes directly for their exact wording. This article contains no dosing, route or administration guidance. All products supplied by Peptide Labs are sold strictly for in-vitro laboratory research and are not intended for human or veterinary use.
Aussie Peptides closed on 20 October 2026 after a 40% off closing sale. The owner says the TGA shut it down. Here is what is known.
ResearchWhat the GLOW peptide blend contains (GHK-Cu, BPC-157 and TB-500), how its certificate is read, and what the published research covers.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides